Why in news
Ozempic, a weight-loss drug, has become a global sensation due to its effectiveness in weight management and diabetes control.
Celebrities' endorsements and rising demand have led to supply shortages in various countries, drawing attention to its potential and challenges in accessibility.
What is Ozempic and Semaglutide
Semaglutide is the generic name for Ozempic (injectable) and Rybelsus (oral form), a class of drugs called Glucagon-like peptide-1 (GLP-1) receptor agonists.
It works by mimicking a hormone in the body that slows digestion, reduces appetite, and stimulates insulin release, helping with weight loss and blood sugar control.
Ozempic was approved in 2017 for type 2 diabetes, and Wegovy (another injectable semaglutide) was approved for chronic weight management in 2021.
Concerns in India
Semaglutide's high price (₹10,000/month) makes it inaccessible to many in India, where out-of-pocket health expenditure is high.
Common side effects include nausea, bloating, and vomiting. Some patients also experience serious issues like pancreatitis.
Injectable forms are not yet widely available in India, leading to long wait times.
The drug is primarily recommended for those with obesity or type 2 diabetes, particularly those at high cardiovascular risk. It's not a first-line weight loss option.
There's a growing black market for semaglutide, raising concerns about misuse and unsafe self-medication.
COMMENTS